Developing 3D cell models for high-throughput antibody-drug conjugate screening in cancer
Presented at the American Association for Cancer Research (AACR) Meeting 2026
Peilin Tian1,2, Morgan Hamon3*, Sean Porazinski3, Maria Kavallaris2,4, Kristopher A Kilian1,2,5 and J Justin Gooding1,2
1. School of Chemistry, UNSW Sydney, Australia. Corresponding author: peilin.tian@unsw.edu.au
2. Australian Centre for NanoMedicine, UNSW, Sydney, Australia
3. Inventia Life Science, Alexandria, NSW, Australia. * Presenting author.
4. Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Australia
5. School of Materials Science and Engineering, UNSW, Sydney, Australia
Preclinical ADC screening often fails to capture how therapies behave in human tumors. This study shows how the RASTRUM™ Allegro platform was used to build high-throughput 3D bioprinted patient-derived colorectal cancer models for testing a CEACAM5-targeted ADC across two CRC subtypes.
The bioprinted tumoroid models preserved subtype-specific biology and enabled comparison of ADC activity against standard-of-care therapies in a more tumor-relevant 3D environment. Results showed clear subtype-dependent response, including stronger ADC activity in the responsive subtype despite similar target expression across both models.
This workflow supports scalable, reproducible ADC screening and helps reveal clinically relevant differences in therapeutic response and resistance.